WallStreetZenWallStreetZen

NASDAQ: RVPH
Reviva Pharmaceuticals Holdings Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsDividendOwnership

Analyst price target for RVPH

Based on 4 analysts offering 12 month price targets for Reviva Pharmaceuticals Holdings Inc.
Min Forecast
$10.00+107.04%
Avg Forecast
$14.25+195.03%
Max Forecast
$18.00+272.67%

Should I buy or sell RVPH stock?

Based on 4 analysts offering ratings for Reviva Pharmaceuticals Holdings Inc.
Strong Buy
Strong Buy
2 analysts 50%
Buy
2 analysts 50%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their RVPH stock forecasts and price targets.

RVPH stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
Roth MKM
Bottom 13%
13
Strong BuyInitiates Coverage On$12.00+148.45%2023-09-20
HC Wainwright & Co.
Bottom 1%
1
BuyReiterates$10.00+107.04%2023-08-16
Benchmark
Bottom 5%
5
BuyInitiates Coverage On$17.00+251.97%2023-06-08
Maxim Group
Bottom 2%
2
Strong BuyMaintains$18.00+272.67%2023-05-03

1 of 1

Forecast return on equity

Is RVPH forecast to generate an efficient return?
Company
-754.46%
Industry
12.77%
Market
48.67%
RVPH's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is RVPH forecast to generate an efficient return on assets?
Company
-103.29%
Industry
1.44%
RVPH is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

RVPH vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
RVPH$4.83$14.25+195.03%Strong Buy
VXRT$0.72$4.00+454.79%Strong Buy
CUE$2.44$11.00+350.82%Strong Buy
CTXR$0.69$4.00+478.03%Buy
GLSI$8.56$38.00+343.93%Buy
View Top Biotech Stocks

Reviva Pharmaceuticals Holdings Stock Forecast FAQ

Is Reviva Pharmaceuticals Holdings Stock a good buy in 2023, according to Wall Street analysts?

The consensus among 4 Wall Street analysts covering (NASDAQ: RVPH) stock is to Strong Buy RVPH stock.

Out of 4 analysts, 2 (50%) are recommending RVPH as a Strong Buy, 2 (50%) are recommending RVPH as a Buy, 0 (0%) are recommending RVPH as a Hold, 0 (0%) are recommending RVPH as a Sell, and 0 (0%) are recommending RVPH as a Strong Sell.

If you're new to stock investing, here's how to buy Reviva Pharmaceuticals Holdings stock.

What is RVPH's forecast return on equity (ROE) for 2023-2024?

(NASDAQ: RVPH) forecast ROE is -754.46%, which is considered weak.

What is RVPH's Price Target?

According to 4 Wall Street analysts that have issued a 1 year RVPH price target, the average RVPH price target is $14.25, with the highest RVPH stock price forecast at $18.00 and the lowest RVPH stock price forecast at $10.00.

On average, Wall Street analysts predict that Reviva Pharmaceuticals Holdings's share price could reach $14.25 by Sep 20, 2024. The average Reviva Pharmaceuticals Holdings stock price prediction forecasts a potential upside of 195.03% from the current RVPH share price of $4.83.

What is RVPH's forecast return on assets (ROA) for 2023-2024?

(NASDAQ: RVPH) forecast ROA is -103.29%, which is lower than the forecast US Biotechnology industry average of 1.44%.
©2023 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.